Pamidronate Disodium (Aredia®)

Common name: Pamidronate Disodium
Brand name: Aredia®
 

What is Pamidronate Disodium?

Pamidronate Disodium belongs to the bisphosphonate class of drugs that is used to treat osteoporosis (bone thinning). It works by reducing the breakdown of bone.


How is Pamidronate Disodium administered?

Pamidronate disodium is administered intravenously.
 

What are possible side effects of this treatment?

Everyone responds differently to treatments for bone metastases – some experience many side effects while others experience very few. Below are some side effects experienced by those who received pamidronate disodium. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Abdominal pain
  • Bone pain
  • Difficulty sleeping
  • Headache
  • Loss of appetite
  • Nausea / vomiting
  • Weakness
 

Is Pamidronate Disodium covered in my province or territory?*

Pamidronate disodium is covered by provincial drug programs in:
  • Alberta
  • British Columbia
  • Manitoba
  • Northwest Territories
  • Nunavut
  • Ontario
  • Prince Edward Island
  • Quebec
  • Saskatchewan
  • Yukon
Pamidronate Disodium is not covered by provincial drug programs in:
  • New Brunswick
  • Newfoundland & Labrador
  • Nova Scotia

*Source: http://drugcoverage.ca/en-ca/search-results.aspx?ID=9766

Last Reviewed: July 2017




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Université de Sherbrooke Researchers’ Findings Published in Cancer Research

Sherbrooke, November 16, 2017 – Prostate cancer, the most common cancer in men, affects one out of seven Canadian men.
More

12 innovative Canadian prostate cancer researchers set out to make new Discoveries

Toronto, ON – September 28, 2017: 12 forward-thinking Canadian prostate cancer researchers have been rewarded for their innovation with Movember Discovery Grants.
More

Gray Tools '2017 Together We Are Stronger' campaign a success in creating awareness and raising funds for prostate cancer

BRAMPTON, Ontario, Sept 26, 2017 (GLOBE NEWSWIRE) -- Gray Tools Canada Inc, in cooperation with Prostate Cancer Canada, is proud to announce that its “2017 Together We Are Stronger” initiative raised $4,000, which will go directly towards funding valuable research that is needed to improve the way we diagnose, treat, and support men living with the disease.
More


Click here for news archive